Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma

Recruiting now · Phase 2

Conditions studied: Mantle Cell Lymphoma (MCL)

In brief

This is a single- arm, open-label, multicenter, phase II study to evaluate Acalabrutinib plus Rituximab for the treatment of elderly or low- to intermediate-risk younger untreated mantle cell lymphoma

Key facts

Study ID

NCT06846489

Run by

Sun Yat-sen University

People needed

50

Starts

2025-04-14

Expected to finish

2033-02-20

Last updated by the study team

2025-06-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Sun yat-sen university cancer center, Sun yat-sen university — Guangzhou, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.